Cedar Grove Capital Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and LENSAR, Inc. (NASDAQ: LNSR), a global medical technology company focused on ...

Alcon will buy Lensar’s outstanding shares for $14 per share. The deal is expected to close in the second half of 2025. Perspective from John A. Hovanesian, MD, FACS Alcon will expand its ...

March 24, 2025 (GLOBE NEWSWIRE) -- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and LENSAR, Inc. (NASDAQ: LNSR), a global medical technology ...

--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and LENSAR, Inc. (NASDAQ: LNSR), a global medical technology company focused on ...

The acquisition includes ALLY Robotic Cataract Laser Treatment System™, LENSAR’s proprietary Streamline® software technology and LENSAR legacy laser system, building Alcon’s femtosecond ...

In its first quarter 2025 investor letter, Cedar Grove Capital Management emphasized stocks such as LENSAR, Inc. (NASDAQ:LNSR). LENSAR, Inc. (NASDAQ:LNSR) is a commercial-stage medical device company.

Eye care company Alcon Inc., which has a major presence in North Texas, plans to buy Lensar Inc. in a deal valued up to $430 million. Orlando-based Lensar (Nasdaq: LNSR) is a laser cataract ...